FAQ: HeartBeam Inc.'s VALID-ECG Study and Its Impact on Cardiac Care

What is the main finding of the VALID-ECG study?

The VALID-ECG study found that HeartBeam’s synthesized 12-lead ECG has a 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment, as presented at the Heart Rhythm Society conference.

Why is HeartBeam’s ECG technology significant?

HeartBeam’s technology is significant because it offers a compact, patient-friendly solution for accurate, on-demand arrhythmia monitoring outside traditional medical facilities, potentially transforming cardiac care.

How does HeartBeam’s device compare to standard ECGs?

HeartBeam’s credit card-sized device demonstrated a 93.4% diagnostic agreement with standard ECGs in the VALID-ECG study, validating its accuracy and portability.

Who presented the VALID-ECG study results?

Dr. Thomas Deering of Piedmont Heart Institute presented the VALID-ECG study results at the Heart Rhythm Society’s annual meeting in San Diego.

When did HeartBeam file for FDA submission?

HeartBeam filed for FDA submission of its ECG synthesis software in January 2025, as part of its steps towards U.S. commercialization.

What is HeartBeam’s Early Access Program?

HeartBeam’s Early Access Program is designed to refine clinical workflows and prepare for U.S. market entry, pending FDA clearance for its ECG technology.

Where can I find more information about HeartBeam Inc.?

More information about HeartBeam Inc. can be found on their website at www.HeartBeam.com or in the company’s newsroom at https://ibn.fm/BEAT.

What are the implications of HeartBeam’s technology for cardiac care?

HeartBeam’s technology could redefine cardiac health management by enabling physicians to identify cardiac health trends and acute conditions outside medical facilities, offering actionable heart intelligence wherever the patient is.